{"id":930541,"date":[{"year":1994,"month":1,"day":6}],"page":"3","source":"本报","region":"","masthead":"科教文卫新闻","special_issue":"","column":"科教文卫集锦","genre":"","count":"333","ytitle":"","mtitle":"治疗慢性乙肝已有首选良药","ftitle":"猪苓多糖注射液对慢性乙肝疗效得到重复验证","authors":["舒明"],"text":[{"type":"paragraph","text":"卫"},{"type":"paragraph","text":"本报讯　(记者舒明)猪苓多糖注射液联合乙肝疫苗治疗慢性乙型肝炎的疗效日前得到重复验证，可望成为治疗慢性乙肝的首选疗法。据对全国60所传染病医院和医科大学附属医院的资料总结表明，E抗原治疗后转阴率为52.73%，肝功能好转率达90%。"},{"type":"paragraph","text":"“猪苓多糖注射液联合乙肝疫苗治疗慢性乙肝”是由国家肝炎重点攻关单位之一、上海市传染病医院院长巫善明教授领导的慢性肝炎课题组于1984年在国内最早提出。全国各地医院近年来对此进行了重复验证并得出上述令人欣喜的结论，而采用常规肝炎药物治疗的对照组病例，e抗原转阴率仅为11.79%。苏州市第五医院将该疗法与进口干扰素作对照，发现两者具有相同功效。"}]}